Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the completion of the transaction, the chief financial officer now owns 105,162 shares of the company’s stock, valued at approximately $1,107,355.86. This represents a 9.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bioventus Price Performance

Shares of NYSE BVS opened at $11.00 on Friday. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a fifty day moving average of $11.86 and a 200 day moving average of $9.77. The firm has a market cap of $892.71 million, a PE ratio of -18.03 and a beta of 0.79. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Bioventus (NYSE:BVS) last announced its earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. The business had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. During the same quarter last year, the business earned $0.05 earnings per share. As a group, research analysts predict that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Several large investors have recently bought and sold shares of BVS. Virtus Fund Advisers LLC purchased a new position in shares of Bioventus in the third quarter valued at approximately $42,000. Quest Partners LLC acquired a new position in Bioventus in the 3rd quarter valued at $51,000. Quarry LP purchased a new position in Bioventus in the 3rd quarter valued at $59,000. HB Wealth Management LLC acquired a new stake in Bioventus during the 2nd quarter worth $60,000. Finally, Covestor Ltd purchased a new stake in shares of Bioventus during the third quarter worth $69,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BVS has been the subject of a number of recent analyst reports. Craig Hallum lifted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group lifted their price target on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.